Natl Conf Hum Retroviruses Relat Infect (1st). 1993 Dec 12-16;:135.
To investigate the effect of R on ddI kinetics and the safety of the
combination, 12 patients maintained on ddI (167 or 250 mg twice daily)
received ddI in the morning of day 1. On days 2 to 13, they received
once daily R (300 mg/day, 8 patients; 600 mg/day, 4 patients) with their
twice daily doses of ddI. On days 1 and 13, thirteen blood samples were
obtained over 12 hours for ddI measurement (HPLC). Mean (+/-SD) ddI
kinetic parameters for 11 patients are presented (table: see text). R
did not affect ddI pharmacokinetics (p greater than 0.05 for all
comparisons; 97 percent power to detect a 20 percent change in AUC). No
changes in ECGs or electrolytes were noted during the study.
Coadministration of R and ddI will not necessitate changes in ddI dose
in symptomatic HIV infected patients.
Body Composition Body Weight Human Male Zidovudine/*PHARMACOKINETICS